Clinical efficacy of complement c5a inhibition by ifx-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab

: Circulating concentrations of the split complement factor C5a are significantly increased in hidradenitis suppurativa (HS)1 . C5a exerts strong chemotaxis and activation of neutrophils at the inflammatory areas so that blockade may be a promising therapeutic target. IFX-1 is a monoclonal IgG4 kappa antibody that selectively binds to C5a and blocks its biological activity (data on file at InflaRx).